Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMAT - ultrafast tomography for coronary artery disease -- Ignore unavailable to you. Want to Upgrade?

To: westpacific who wrote (2729)	10/22/1998 11:23:00 AM
From: Bruce Rozenblit	Read Replies (1) \| Respond to of 3725

I totally agree with you. The potential for sales tied to drug applications is enormous. Again, politics will be the major road block. Currently, there is some insurance company study floating around that says the scanner does not pay back for 7 seven years when doing blanket screening. That's a lot of crap because you can make economic studies come up with any desired outcome depending upon what information is used and what is omitted and how the information is weighted. This is new science and their standard "models" used for the calculations don't apply. The company should attack the study and develop its own.